In clinical trials, Wegovy was shown to reduce body weight in people with body mass indexes, or BMIs, of 27 or greater by around 15% over 68 weeks
A named, registered independent prescriber reviews your consultation and issues your prescription
Other priority research questions to be addressed relevant to repurposing GLP-1 RAs as psychiatric drugs include target engagement studies, CNS penetration, drug-drug interaction studies with concomitant drugs, dose-finding studies, and health systems research that endeavors to determine optimal integrated care pathways
The economics of this system deserve scrutiny
Treatment Options at WeightWatchers WeightWatchers really pushes Wegovy, a semaglutide, because it has a deal with the manufacturer, but it offers a number of other GLP-1 medications as well
Schedule a consult with Dr D